Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:administeredBy |
gptkb:tablet
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01EG03
|
| gptkbp:brand |
gptkb:Lumakras
gptkb:Lumykras |
| gptkbp:CASNumber |
2296729-00-3
|
| gptkbp:developer |
gptkb:Amgen
|
| gptkbp:eliminationHalfLife |
5.5 hours
|
| gptkbp:hasMolecularFormula |
C30H30F2N6O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
sotorasib
|
| gptkbp:indication |
KRAS G12C-mutated locally advanced or metastatic NSCLC
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
KRAS G12C inhibitor
|
| gptkbp:metabolism |
gptkb:CYP3A4
|
| gptkbp:molecularWeight |
560.6 g/mol
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:proteinBinding |
89%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue hepatotoxicity |
| gptkbp:target |
gptkb:KRAS_G12C
|
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:bfsParent |
gptkb:KRAS
|
| gptkbp:bfsLayer |
5
|